HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 76.5%

Neg 0% Neu 0% Pos 76.5%

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $12 to $15.